Evidence map›Paper›PMID 35313331›Full record

ArticleMolecular cancer therapeutics2022

Porcupine Inhibition Disrupts Mitochondrial Function and Homeostasis in WNT Ligand-Addicted Pancreatic Cancer.

Kristina Y Aguilera, Thuc Le, Rana Riahi, Anna R Lay, Stefan Hinz, Edris A Saadat, Ajay A Vashisht, James Wohlschlegel, Timothy R Donahue, Caius G Radu and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Molecular cancer therapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Recent advances in drug delivery and targeting for the treatment of pancreatic cancer.Journal of controlled release : official journal of the Controlled Release Society · 2024
    Review
  3. Article
  4. The role of Evi/Wntless in exporting Wnt proteins.Development (Cambridge, England) · 2023
    Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Kristina Y AguileraDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, California.ORCID 0000-0002-0877-9798
Thuc LeDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, California.
Rana RiahiDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, California.
Anna R LayDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, California.
Stefan HinzDepartment of Population Sciences, Beckman Research Institute, City of Hope, Duarte, California.ORCID 0000-0003-3184-2983
Edris A SaadatDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, California.ORCID 0000-0002-7761-5420
Ajay A VashishtDepartment of Biological Chemistry, University of California, Los Angeles, California.
James WohlschlegelDepartment of Biological Chemistry, University of California, Los Angeles, California.
Timothy R DonahueDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, California.ORCID 0000-0002-1175-2545
Caius G RaduDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, California.ORCID 0000-0002-9338-5397
David W DawsonDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, California.ORCID 0000-0002-0215-5861
University of California, Los Angeles · USCity of Hope · US

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Yvonne Yu-Hsuan Chen · 2017 to 2026
$25.2M
TUMOR CELL SURFACES AND CHROMOSOMEST32CA009056 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Gay M Crooks, David A. Nathanson · 1985 to 2026
$10.5M
Project 3: Role of the pancreatic fibroinflammatory microenvironment in obesity-promoted pancreatic cancerP01CA236585 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI EIBL, GUIDO ERWIN MICHAEL · 2020 to 2024
$5.6M
Targeting KRAS and adenosine mediated immunosuppression in pancreatic cancerR01CA260678 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DONAHUE, TIMOTHY R, RADU, CAIUS GABRIEL · 2021 to 2025
$3.0M
NCI NIH HHS P01 CA236585NCI NIH HHS P30 CA016042NCI NIH HHS P50 CA211015NCI NIH HHS R01 CA260678NCI NIH HHS T32 CA009056
6 · The paper itself

Abstract

WNT signaling promotes pancreatic ductal adenocarcinoma (PDAC) through diverse effects on proliferation, differentiation, survival, and stemness. A subset of PDAC with inactivating mutations in ring finger protein 43 (RNF43) show growth dependency on autocrine WNT ligand signaling and are susceptible to agents that block WNT ligand acylation by Porcupine O-acyltransferase, which is required for proper WNT ligand processing and secretion. For this study, global transcriptomic, proteomic, and metabolomic analyses were performed to explore the therapeutic response of RNF43-mutant PDAC to the Porcupine inhibitor (PORCNi) LGK974. LGK974 disrupted cellular bioenergetics and mitochondrial function through actions that included rapid mitochondrial depolarization, reduced mitochondrial content, and inhibition of oxidative phosphorylation and tricarboxylic acid cycle. LGK974 also broadly altered transcriptional activity, downregulating genes involved in cell cycle, nucleotide metabolism, and ribosomal biogenesis and upregulating genes involved in epithelial-mesenchymal transition, hypoxia, endocytosis, and lysosomes. Autophagy and lysosomal activity were augmented in response to LGK974, which synergistically inhibited tumor cell viability in combination with chloroquine. Autocrine WNT ligand signaling dictates metabolic dependencies in RNF43-mutant PDAC through a combination of transcription dependent and independent effects linked to mitochondrial health and function. Metabolic adaptations to mitochondrial damage and bioenergetic stress represent potential targetable liabilities in combination with PORCNi for the treatment of WNT ligand-addicted PDAC.

Indexed as

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsWnt Signaling PathwayAcyltransferasesCell Line, TumorCell ProliferationHomeostasisHumansLigandsMembrane ProteinsMitochondriaProteomicsAcyltransferasesLigandsMembrane ProteinsPORCN protein, human

Identifiers

PMID35313331
PMCPMC9167706
OpenAlexW4220825310

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.